Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Medical therapy v. PCI in stable coronary artery disease: a cost-effectiveness analysis.

Wijeysundera HC, Tomlinson G, Ko DT, Dzavik V, Krahn MD.

Med Decis Making. 2013 Oct;33(7):891-905. doi: 10.1177/0272989X13497262. Epub 2013 Jul 25.

PMID:
23886676
[PubMed - indexed for MEDLINE]
2.

Intravascular ultrasound to guide percutaneous coronary interventions: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(12):1-97. Epub 2006 Apr 1.

PMID:
23074482
[PubMed]
Free PMC Article
3.

Drug-eluting stents: a systematic review and economic evaluation.

Hill RA, Boland A, Dickson R, Dündar Y, Haycox A, McLeod C, Mujica Mota R, Walley T, Bagust A.

Health Technol Assess. 2007 Nov;11(46):iii, xi-221. Review.

PMID:
17999841
[PubMed - indexed for MEDLINE]
Free Article
4.

Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.

Magnuson EA, Farkouh ME, Fuster V, Wang K, Vilain K, Li H, Appelwick J, Muratov V, Sleeper LA, Boineau R, Abdallah M, Cohen DJ; FREEDOM Trial Investigators.

Circulation. 2013 Feb 19;127(7):820-31. doi: 10.1161/CIRCULATIONAHA.112.147488. Epub 2012 Dec 31.

PMID:
23277307
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Long-term clinical outcomes and cost-effectiveness analysis in multivessel percutaneous coronary interventions: comparison of drug-eluting stents, bare-metal stents and a mixed approach in patients at high and low risk of repeat revascularisation.

Varani E, Guastaroba P, Di Tanna GL, Saia F, Balducelli M, Campo G, Vignali L, Rossi R, Manari A, Piovaccari G, De Palma R, Marzocchi A.

EuroIntervention. 2010 Apr;5(8):953-61. doi: 10.4244/.

PMID:
20542781
[PubMed - indexed for MEDLINE]
6.

Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease.

Wisløff T, Atar D, Sønbø Kristiansen I.

Am J Ther. 2013 Nov-Dec;20(6):596-601. doi: 10.1097/MJT.0b013e3182211a01.

PMID:
21822114
[PubMed - indexed for MEDLINE]
7.

Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.

Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.

Arch Cardiovasc Dis. 2013 Nov;106(11):554-61. doi: 10.1016/j.acvd.2013.06.056. Epub 2013 Nov 11.

PMID:
24231052
[PubMed - indexed for MEDLINE]
8.

Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario.

Goeree R, Bowen JM, Blackhouse G, Lazzam C, Cohen E, Chiu M, Hopkins R, Tarride JE, Tu JV.

Int J Technol Assess Health Care. 2009 Apr;25(2):196-207. doi: 10.1017/S0266462309090254. Epub 2009 Mar 31.

PMID:
19331710
[PubMed - indexed for MEDLINE]
9.

Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.

Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW; ORAR III Investigators.

Catheter Cardiovasc Interv. 2012 Sep 1;80(3):385-94. doi: 10.1002/ccd.23352. Epub 2011 Dec 8.

PMID:
22109997
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.

Bonaventura K, Leber AW, Sohns C, Roser M, Boldt LH, Kleber FX, Haverkamp W, Dorenkamp M.

Clin Res Cardiol. 2012 Jul;101(7):573-84. doi: 10.1007/s00392-012-0428-2. Epub 2012 Feb 21.

PMID:
22350752
[PubMed - indexed for MEDLINE]
11.

Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.

Rodriguez AE, Maree A, Tarragona S, Fernandez-Pereira C, Santaera O, Rodriguez Granillo AM, Rodriguez-Granillo GA, Russo-Felssen M, Kukreja N, Antoniucci D, Palacios IF, Serruys PW; ORAR III Investigators.

EuroIntervention. 2009 Jun;5(2):255-64.

PMID:
20449934
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada.

Brophy JM, Erickson LJ.

Int J Technol Assess Health Care. 2005 Summer;21(3):326-33.

PMID:
16110712
[PubMed - indexed for MEDLINE]
14.

Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model.

Garg P, Cohen DJ, Gaziano T, Mauri L.

J Am Coll Cardiol. 2008 May 13;51(19):1844-53. doi: 10.1016/j.jacc.2008.01.042.

PMID:
18466798
[PubMed - indexed for MEDLINE]
Free Article
15.

Analysis of the cost-effectiveness of drug-eluting and bare-metal stents in coronary disease.

Ferreira E, Araújo DV, Azevedo VM, Rodrigues CV, Ferreira A Jr, Junqueira Cde L, Amino JG, Farias ML, Farias Neto A, de Albuquerque DC.

Arq Bras Cardiol. 2010 Mar;94(3):286-92, 306-12. English, Portuguese.

PMID:
20730255
[PubMed - indexed for MEDLINE]
Free Article
16.

Long-term clinical outcomes in patients treated with drug-eluting compared to bare-metal stents for the treatment of transplant coronary artery disease.

Lee MS, Yang T, Kandzari D, Mahmud E, Liao H, Kirtane A.

Catheter Cardiovasc Interv. 2012 Oct 1;80(4):533-8. doi: 10.1002/ccd.23379. Epub 2012 Mar 14.

PMID:
21953766
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data.

Bischof M, Briel M, Bucher HC, Nordmann A.

Value Health. 2009 Jul-Aug;12(5):649-56. doi: 10.1111/j.1524-4733.2009.00513.x.

PMID:
19490551
[PubMed - indexed for MEDLINE]
18.

Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis.

Kuukasjärvi P, Räsänen P, Malmivaara A, Aronen P, Sintonen H.

Int J Technol Assess Health Care. 2007 Fall;23(4):473-9. Review.

PMID:
17937836
[PubMed - indexed for MEDLINE]
19.

A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.

Ribichini F, Tomai F, De Luca G, Boccuzzi G, Presbitero P, Pesarini G, Ferrero V, Ghini AS, Pastori F, De Luca L, Zavalloni D, Soregaroli D, Garbo R, Franchi E, Marino P, Minelli M, Vassanelli C.

J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):192-9. doi: 10.2459/JCM.0b013e32831f9176.

PMID:
19377384
[PubMed - indexed for MEDLINE]
20.

Coronary artery stents: a rapid systematic review and economic evaluation.

Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, Mujica Mota R, Reaney A, Roberts D, Williamson P, Walley T.

Health Technol Assess. 2004 Sep;8(35):iii-iv, 1-242. Review.

PMID:
15361315
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk